This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Winners & Losers:

Shares of (CRM - Get Report) gained $4.34, or 6.9%, to $67.01 after it raised full-year guidance and reported strong revenue growth in the first quarter. First-quarter revenue grew 52% to $247.6 million, and topped Street expectations of $235.8 million. Profit grew to $9.6 million, or 8 cents a share, from $730,000, or 1 cent a share, a year ago. Analysts were expecting EPS of 7 cents. For the full year, said it expects revenue to range from $1.06 billion to $1.065 billion, up from a previous projection of $1 billion to $1.02 billion and better than analysts' estimates of $1.045 billion in revenue.

Video-games retailer GameStop (GME - Get Report) lost $3.39, or 6.7%, to $47.45 after the company offered guidance that failed to impress investors. For the second quarter, GameStop said it expects EPS to range from 26 cents to 28 cents compared to earnings of 14 cents the year before. Analysts are looking for EPS of 26 cents. GameStop said full-year EPS could be range from $2.30 to $2.39. That compares to Street expectations of $2.33.

Meanwhile, shares of Houston-based ExpressJet Holdings (XJT), which operates airline Continental Express, fell 42.5% to $1.57. The company said it would cut back on its schedule by 30%, citing higher fuel prices.

On the deal front, Myriad Genetics (MYGN - Get Report)shares rose after the company announced an agreement with Danish company Lundbeck A/S worth up to $350 million. Lundbeck, which markets the second most prescribed Alzheimer's drug in Europe, Ebixa (called Namenda in the U.S.), will pay Myriad $100 million upfront for outside-the-U.S. rights to Myriad's late-stage Alzheimer's drug Flurizan.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CRM $79.97 0.00%
GME $36.01 0.00%
MYGN $44.09 0.00%
PFE $32.79 0.00%
AAPL $117.81 0.00%


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs